Rationale for current therapies in Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1747-1761

  Romrell, Janet ^a   Fernandez, Hubert H ^a,b   Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Antipsychotics; Clozaril; Evidence; Medication; Parkinson's disease; Pharmacotherapy; Review; Seroquel

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE MESILATE; PRAMIPEXOLE; PROFENAMINE; PROPANTHELINE BROMIDE; QUETIAPINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TOLTERODINE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

AGRANULOCYTOSIS; ANKLE EDEMA; BLOOD BRAIN BARRIER; BRADYCARDIA; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DYSKINESIA; ERYTHEMA; ERYTHROMELALGIA; HALLUCINATION; HUMAN; HYPERSALIVATION; IMPOTENCE; INSOMNIA; INTESTINE ABSORPTION; LEUKOPENIA; LIVER TOXICITY; MEMORY DISORDER; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PARKINSON DISEASE; QUALITY OF LIFE; RASH; REVIEW; SEDATION; SIDE EFFECT; SKIN FIBROSIS; SKIN INFLAMMATION; SLEEP DISORDER; SWEAT GLAND DISEASE; TACHYCARDIA; THALAMOTOMY; TREMOR; URINARY URGENCY; URINE COLOR; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 0142148157     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1747     Document Type: Review

References (145)

1. OLANOW CW, WC KOLLER: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology (1998) 50(3 Suppl. 3): S1-S57.
2. RASCOL O, BROOKS DJ, KORCZYN AD et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(20):1484-1491.
3. PARKINSON STUDY GROUP: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA (2000) 284(15):1931-1938.
4. HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ: Accuracy of clinical diagnosis of Idiopathic Parkinson's Disease: a clinicopathologic study of 100 cases. J. Neurol. Neurosurg. Psychiatry (1992) 55:181-184.
5. RAJPUT AH, ROZDILSKY B, RAJPUT A, ANG L: Levodopa efficacy and pathological basis of Parkinson syndrome. Clin. Neuropharmacol. (1990) 13(6):553-558.
6. DIAMOND SG, MARKHAM CH, HOEHN MM, MCDOWELL FH, MUENTER MD: Effect of age at onset on progression and mortality in Parkinson's disease. Neurology (1989) 39(9):1187-1190.
7. RAJPUT AH, UITII RJ, RAJPUT AH, OFFORD KP: Timely levadopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat. Disord. (1997) 3(3):159-165.
8. MOURADIAN MM, JUNCOS JL, FABBRINI G et al.: Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann. Neurol. (1988) 24(3):366-371.
9. NUTT JG, FELLMAN JH: Pharmacokinetics of levadopa. Clin. Neuropharmacol. (1984) 7:35-49.
10. KOLLER WC, PAHWA R: Treating motor fluctuations with controlled-release levodopa preparations. Neurology (1994) 44(7 Suppl. 6):S23-S28.
11. JANKOVIC J, TOLOSA E: Therapeutic strategies in Parkinson's disease. In: Parkinson's Disease and Movement Disorders, Jankovic J, Marsden D (Eds), Williams and Wilkins, Baltimore, USA (1998):191-220.
12. BLOCK G, LISS C, REINES S, IRR J, NIBBELINK D: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur. Neurol. (1997) 37(1):23-27.
13. KARSTAEDT PJ, PINCUS JH: Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch. Neurol. (1992) 49(2):149-51.
14. PINCUS JH, K. BARRY: Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch. Neurol. (1987) 44(3):270-272.
15. OLANOW CW RL, WATTS WC KOLLER: An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology (2001) 56(11 Suppl. 5): S1-S88.
16. KURTH MC: Using liquid levodopa in the treatment of Parkinson's disease. a practical guide. Drugs Aging (1997) 10(5):332-340.
17. JANKOVIC J: Levodopa strengths and weaknesses. Neurology (2002) 58(4 Suppl. 1):S19-S32.
18. FAHN S: Adverse effects of levadopa. In: The Scientific Basis for the Treatment of Parkinson's Disease, Olanow CW, Lieberman AN (Eds), Parthenon Publishing Group, Carnforth, UK (1992):89-112.
19. QUINN N P, CRITCHLEY CD, MARSDEN: Young onset Parkinson's disease. Mov. Disord. (1987) 2(2):73-91.
20. KOSTIC V, PRZEDBORSKI S, FLASTER E, STERNIC N: Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology (1991) 41(2 Pt 1):202-205.
21. GERSHANIK OS: Early-onset Parkinsonism. In: Parkinson's Disease and Movement Disorders, Jankovic J, Tolosa E (Eds), Williams & Wilkins, Baltimore, USA (1993):235-252.
22. WAGNER ML, FEDAK MN, SAGE JI, MARK MH: Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann. Clin. Lab. Sci. (1996) 26:389-395.
23. RAJPUT AH, FENTON ME, BIRDI S et al.: Clinical-pathological study of levodopa complications. Mov. Disord. (2002) 17(2):289-296.
24. DJALDETTI R, MELAMED E: Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann. Neurol. (1996) 39(3):400-404.
25. DJALDETTI R, INZELBERG R, GILADI N et al.: Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov. Disord. (2002) 17(2):297-302.
26. HUTTON JT, METMAN LV, CHASE TN et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923. TDS: a double-blind, placebo-controlled study. Mov. Disord. (2001) 16(3):459-463.
27. FAHN S: Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch. Neurol. (1999) 56(5):529-535.
28. QUINN N, CRITCHLEY P, PARKES D, MARSDEN CD: When should levodopa be started? Lancet (1986) 2(8513):985-986.
29. AGID Y, AHLSKOG E, ALBANESE A et al.: Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov. Disord. (1999) 14(6):911-913.
30. LEES AJ, KATZENSCHLAGER R, HEAD J, BEN-SHLOMO Y: Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology (2001) 57(9):1687-1694.
31. CALNE DB: Treatment of Parkinson's disease. N. Engl. J. Med. (1993) 329(14):1021-1027.
32. CALNE DB, BURTON K, BECKMAN J, MARTIN WR: Dopamine agonists in Parkinson's disease. Can. J. Neurol. Sci. (1984) 11 (1 Suppl.):221-224.
33. SCHACHTER M, BEDARD P, DEBONA AG et al.: The role of D-1 and D-2 receptors. Nature (1980) 286:157-159.
34. PERACHON S, SCHWARTZ JC, SOKOLOFF P: Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2 and D-3 receptors. Eur. J. Pharmacol. (1999) 366:293-300.
35. OLANOW CW: Dopamine agonists in early Parkinson's disease. In: The Comprehensive Management of Parkinson's disease, Stern HB, Hurtig HI (Eds), PMA Publishing Co, New York, USA (1988):89-100.
36. MONTASTRUC JL, RASCOL O, SENARD JM: Current status of dopamine agonists in Parkinson's disease management. Drugs (1993) 46(3):384-393.
37. SOKOLOFF P, GIROS B, MARTRES M-P et al.: Molecular cloning and characterization of novel dopamine receptor (D3) as a target for neuroleptics. Nature (1990) 347:146-151.
38. CARVEY PM: The case for neuroprotection with dopamine (DA) agonists. Mov. Disord (1996) 11(Suppl. 1):265.
39. CHASE TN, BARONTI F, FABBRINI G, HEUSER IJ, JUNCOS JL, MOURADIAN MM: Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology (1989) 39(11 Suppl. 2):7-1; Discussion: 19.
40. OLANOW CW, JENNER P, BROOKS D: Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. (1998) 44(3 Suppl. 1):S167-S174.
41. FRUCHT S, ROGERS JD, GREENE PE, GORDON MF, FAHN S: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 52(9):1908-1910.
42. OLANOW CW, SCHAPIRA AH, ROTH T: Waking up to sleep episodes in Parkinson's disease. Mov. Disord. (2000) 15(2):212-215.
43. MONTASTRUC JL, BREFEL-COURBON C, SENARD JM et al.: Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin. Neuropharmacol. (2001) 24(3):181-183.
44. RYAN M, SLEVIN JT, WELLS A: Non-ergot dopamine agonist-induced sleep attacks. Pharmacotherapy (2000) 20(6):724-726.
45. SCHAPIRA AH: Sleep attacks (sleep episodes) with pergolide. Lancet (2000) 355(9212):1332-1333.
46. RAJPUT AH: Adverse effects of ergot-derivative dopamine agonists. In: Dopamine agonists in early Parkinson's disease. Olanow CW, Obeso JA (Eds), Wells Medical, Kent, UK (1997):209-216.
47. PFITZENEMEYER P, FOUCHER P, DENNEWALD G et al.: Pleuropulmonary changes induced by ergoline drugs. Eur. Respir. J. (1996) 9:1013-1019.
48. SHAUNAK S, WILKINS A, PILLING JB, DICK DJ: Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J. Neurol. Neurosurg. Psychiatry (1999) 66(1):79-81.
49. LING LH, AHLSKOG JE, MUNGER TM, LIMPER AH, OH JK: Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin. Proc. (1999) 74(4):371-375.
50. ADLER CH, SETHI KD, HAUSER RA et al.: Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology (1997) 49(2):393-399.
51. LIEBERMAN A, RANHOSKY A, KORTS D: Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology (1997) 49(1):162-168.
52. SHANNON KM JP, BENNETT JR JH FRIEDMAN: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology (1997) 49(3):724-728.
53. RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs (1998) 55(Suppl. 1):23-30.
54. CASSARINO DS, FALL CP, SMITH TS, BENNETT JP Jr: Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. (1998) 71(1):295-301.
55. ZOU LL, XU J, JANKOVIC J, HE Y, APPEL SH, LE W: Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahyopyridine in C57BL/6 mice. Neurosci. Lett. (2000) 281:167-170.
56. SCHAPIRA AH: Neuroprotection and dopamine agonists. Neurology (2002) 58(Suppl. 1):S9-S18.
57. DUBOIS B, DANZE F, PILLON B et al.: Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann. Neurol. (1978) 22:26-30.
58. HORROCKS PM, VICARY DJ, REES JE, PARKES JD, MARSDEN CD: Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1973) 36(6):936-941.
59. BROCKS DR: Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J. Pharm. Pharm. Sci. (1999) 2(2):39-46.
60. ARANDA B, PERRIGOT M, MAZIERES L, PIERROT-DESEILLIGNY E: [Bladder sphincter disorders in Parkinson's disease]. Rev. Neurol. (Paris) (1983) 139(4):283-288.
61. GOETZ CG, KOLLER WC, POEWE W et al.: Management of Parkinson's disease: an evidence based review. Mov. Disord. (2002) 17(Suppl. 4):S120-S127.
62. JORGA KM, SEDEK G: Effect of novel COMT-inhibitor tolcapone on L-dopa pharmacokinetics when combined with different Sinemet formulations. Neurology (1995) 45:S465 (Abstract).
63. NUTT JG, WOODWARD WR, BECKNER RM et al.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 44(5):913-919.
64. BAAS H, ZEHRDEN F, SELZER R, KOHNEN R, LOETSCH J, HARDER S: Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin. Pharmacokinet. (2001) 40(5):383-393.
65. RINNE UK, LARSEN JP, SIDEN A, WORM-PETERSEN J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology (1998) 51(5):1309-1314.
66. KURTH MC, ADLER CH, HILAIRE MS et al.: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology (1997) 48(1):81-87.
67. RAJPUT AH, MARTIN W, SAINT-HILAIRE MH, DORFLINGER E, PEDDER S: Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology (1997) 49(4):1066-1071.
68. PARKINSON STUDY GROUP: Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol. (1997) 42(5):747-755.
69. HANSON MR, GALVEZ-JIMENEZ N: Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin. Neurol. (2001) 21(1):15-22.
70. SAWLE GV, BURN DJ, MORRISH PK et al.: The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology (1994) 44(7):1292-1297.
71. BAAS H, BEISKE AG, GHIKA J et al.: Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology (1998) 50(5 Suppl. 5 ):S46-S53.
72. OLANOW CW, JA OBESO: Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology (2000) 55(11 Suppl. 4):S72-S77; Discussion: S78-S81.
73. SCHAPIRA AH JA, OBESO CW OLANOW: The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology (2000) 55(11 Suppl. 4):S65-S68; (Discussion S69-S71).
74. HEIKKILA RE, MANZINO L, CABBAT FS, DUVOISIN RC: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1-2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. (1984) 106:209-210.
75. COHEN G, PASIK P, COHEN B, LEIST A, MYTILINEOU C, YAHR MD: Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. (1984) 106(1):209-210.
76. THE PARKINSON STUDY GROUP: Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. (1989) 321(20):1364-1371.
77. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch. Neurol. (1989) 46(10):1052-1060.
78. OLANOW CW, HAUSER RA, GAUGER L et al.: The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. (1995) 38(5):771-777.
79. PARKINSON STUDY GROUP: Impact of deprenyl and tocopherol treatment on Parkinson's disease in datatop patients requiring levodopa. Ann. Neurol. (1996) 39(1):37-45.
80. PARKINSON STUDY GROUP: Impact of deprenyl and tocopherol treatment on Parkinson's disease in datatop subjects not requiring levodopa. Ann. Neurol. (1996) 39(1):29-36.
81. GILADI N, MCDERMOTT MP, FAHN S et al.: Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 56(12):1712-1721.
82. OLANOW CW, MYLLYLA VV, SOTANIEMI KA et al.: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology (1998) 51(3):825-830.
83. SHOULSON I, OAKES D, FAHN S et al.: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. (2002) 51(5):604-612.
84. SCHWAB RS, ENGLAND AC Jr, POSKANCER DC, YOUNG RR: Amantadine in the treatment of Parkinson's disease. JAMA (1969) 208:1168-1170.
85. METMAN LV, DEL DOTTO P, LEPOOLE K, KONITSIOTIS S, FANG J, CHASE TN: Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. (1999) 56(11):1383-1386.
86. STOOF JC, BOOIJ J, DRUKARCH B: Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin. Neurol. Neurosurg. (1992) 94(Suppl.):S4-S6.
87. FAHN S, ISGREEN WP: Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses. Neurology (1975) 25(8):695-700.
88. RAJPUT A, WALLUKAIT M, RAJPUT AH: 18 month prospective study of amantadine (Amd) for dopa (LD) induced dyskinesias (DK) in idiopathic Parkinson's disease. Can. J. Neurol. Sci. (1997) 24:S23.
89. UITTI RJ, RAJPUT AH, AHLSKOG JE et al.: Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology (1996) 46(6):1551-1556.
90. MERELLO M, NOUZEILLES MI, CAMMAROTA A, LEIGUARDA R: Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin. Neuropharmacol. (1999) 22(5):273-276.
91. MELTZER HY, NATSUBARA S, LEE JC: Classification of typical and atypical psychotic drugs on the basis of D1, D2 and serotonin 2 pk1 values. J. Pharmacol. Exp. Ther. (1989) 251:238-246.
92. MELTZER HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. (1995) 3(2):64-75.
93. ARNT J, SKARSFELD T: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropharmacology (1998) 18:63-101.
94. LEYSEN JE, JANSSEN PM, SCHOTTE A, LUYTEN WH, MEGENS AA: Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacol. Bull. (1993) 112(Suppl. 1):40-54.
95. LAHTI AC, LAHTI RA, TAMINGA CA: New neuroleptics and experimental antipsychotics: future roles, in Advances. In: Neuroleptic Drugs. American Psychiatric Association Press, Washington DC, USA (1996):57-87.
96. RICHELSON E, NELSON A: Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol. (1984) 103:197-204.
97. SEEMAN P, LEE T, CHAU-WONG M et al.: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (1976) 261:717-719.
98. PAKKENBERG H, PAKKENBERG B: Clozapine in the treatment of tremor. Acta Neurol. Scand. (1986) 73(3):295-297.
99. FISHER PA, BASS H, HEFNER R: Treatment of parkinsonian tremor with clozapine. J. Neural. Transm. (1990) 2:233-238.
100. FRIEDMAN JH et al.: Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology (1997) 48(4):1077-1081.
101. JANSEN EN: Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol. Scand. (1994) 89(4):262-265.
102. BONUCCELLI U, CERAVOLO R, SALVETTI S et al.: Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology (1997) 49(6):1587-1590.
103. WOLTERS ECH, HURWITZ TA, MAK E et al.: Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology (1990) 40:832-834.
104. THE PARKINSON STUDY GROUP: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. (1999) 340(10):757-763.
105. THE FRENCH CLOZAPINE PARKINSON STUDY GROUP: Clozapine in drug-induced psychosis in Parkinson's disease. Lancet (1999) 353(9169):2041-2042.
106. GREENE P, COTE L, FAHN S: Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv. Neurol. (1993) 60:703-706.
107. RUGGIERI S, DE PANDIS MF, BONAMARTINI A, VACCA L, STOCCHI F: Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin. Neuropharmacol. (1997) 20(3):204-209.
108. RUI SILVA M, MAGALHAES M, VISEU M, BASTOS LIMA A: Clozapine in the treatment of pyschosis in parkinsonism. J. Neurol. (1995) 242(Suppl. 2):138.
109. ALVIR JMA, LIEBERMAN JA, SAFFERMAN AZ: Clozapine induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. (1993) 329:162-167.
110. HONIGFELD G, ARELLANO F, SETHI J et al.: Reducing clozapine-related morbidity and mortality: 5 years of experience with clozapine national registry. J. Clin. Psychiatry (1998) 59(Suppl. 3):3-7.
111. FERNANDEZ HH, FRIEDMAN JH: Long-term outcome of clozapine use for psychosis among Parkinsonian patients. 7th International Congress on Parkinson's Disease and Movement Disorders, Miami, FL, USA (2002).
112. GOETZ CG, STEBBINS G: Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology (1995) 45:669-671.
113. TROSCH RM, FRIEDMAN JH, LANNON MC et al.: Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov. Disord. (1998) 13:377-382.
114. FRIEDMAN JH, KOLLER W. C, GOLDSTEIN S et al.: BCLOZ: a double-blind, crossover trial comparing clozapine with benztropine for treatment of tremor in Parkinson's disease. Neurology (1996) 46(Suppl.):476 (Abstract).
115. KORSGAARD AG, REEUR L, WERDELIN L: Clozapine in the treatment of tremor: clinical experience since 1986 (abstract). Mov. Disord. (1994) 9(Suppl.):20.
116. AREVALO GJ, OS GERSHANIK: Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov. Disord. (1993) 8(3):349-354.
117. AUZOU P, OZSANCAK C, HANNEQUIN D, MOORE N, AUGUSTIN P: Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol. Scand. (1996) 94(5):329-336.
118. LINAZASORO CG, SUAREZ JA, MARTI'MASSO JF: Clozapine in Parkinson's disease: three years experience. Mov. Disord. (1992) (Suppl.):100.
119. GONSKI P: Clozapine in Parkinson's disease. Lancet (1995) 345(8948):516-517.
120. GONSKI PN: The use of clozapine in Parkinson's disease. Aust. NZ J. Med. (1994) 24(5):585.
121. OSTERGAARD K, DUPONT E: Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol. Scand. (1988) 78(4):349-350.
122. GERSHANIK O, GARCIA S, PAPA S, SCIPIONI O: Analysis of the mechanism of action of clozapine in Parkinson's disease. Mov. Disord. (1992) 7(Suppl. 1):101.
123. RABEY JM, TREVES TA, NEUFELD MY, ORLOV E, KORCZYN AD: Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology (1995) 45(3 Pt 1):432-434.
124. FACTOR SA, BROWN D: Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov. Disord. (1992) 7(2):125-31.
125. BENNETT JP Jr, LANDOW ER, DIETRICH S, SCHUH LA: Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov. Disord. (1994) 9(4):409-14.
126. BENNETT JP Jr, LANDOW ER, SCHUH LA: Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology (1993) 43(8):1551-1555.
127. GRANT S, FITON A: Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs (1994) 43:456-460.
128. ELLIS T, CUDKOWICZ ME, SEXTON PM, GROWDON JH: Clozapine and risperidone treatment of psychosis in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. (2000) 12(3):364-369.
129. ROSEBUSH PI, MAZUREK M. F: Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology (1999) 52:782-785.
130. DAVID SR, TAYLOR CC, KINON BJ, BREIER A: The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. (2000) 22:1085-1096.
131. MECO G, ALESSANDRI A, GIUSTINI P, BONIFATI V: Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov. Disord. (1997) 12(4):610-612.
132. MOORE NA, TYE NC, AXTON MS et al.: The behavioral pharmacology of olanzapine: a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. (1992) 262:545-551.
133. MOORE NA, COLIGARO DO, WONG DT et al.: The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Investig. Drugs (1993) 2:281-293.
134. WOLTERS EC, JANSEN EN, TUYNMAN-QUA HG, BERGMENS PL: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology (1996) 47:1085-1087.
135. MOLHO ES, SA FACTOR: Worsening of motor features of parkinsonism with olanzapine. Mov. Disord. (1999) 14(6):1014-1016.
136. CHURCHYARD A, IANSEK R: Olanzapine as treatment of the neuropsychiatric complications of Parkinson's disease: an open-label study. Mov. Disord. (1998) 13(Suppl. 2):188.
137. WEINER WJ, MINAGAR A, SHULMAN L: Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease. Mov. Disord. (1998) 13(Suppl. 2):62-79.
138. GRAHAM JM, SUSSMAN JD, FORD KS, SAGAR HJ: Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J. Neurol. Neurosurg. Psychiatry (1998) 65(5):774-777.
139. STOVER NP, JUNCOS JL: Olanzapine treatment of Parkinson's patients with psychosis. Neurology (1999) 52(Suppl. 2):A215.
140. AARSLAND D, LARSEN JP, LIM NG, TANDBERG E: Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J. Neuropsychiatry Clin. Neurosci. (1999) 11(3):392-394.
141. GOETZ CG, BLASUCCI LM, LEURGANS S, PAPPERT EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology (2000) 55(6):789-794.
142. MANSON AJ, SCHRAG A, LEES AJ: Low-dose olanzapine for levadopa induced dyskinesias. Neurology (2000) 55:795-799.
143. REDDY S, FACTOR SA, MOLHO ES, FEUSTEL PJ: The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov. Disord. (2002) 17(4):676-681.
144. FERNANDEZ HH, BURKE MA, JACQUES C, FRIEDMAN JH: Long-term quetiapine use for drug induced psychosis among parkinsonian patients. Mov. Disord. (2003) 18:510-515.
145. WEIDEN PJ, IQBAL N, MENDELOWITZ AJ, TANDON R, ZIMBROFF DL, ROSS R: Best clinical practice with ziprasidone: update after one year of experience. J. Psychiatric Pract. (2002) 8:81-98.